Overview

Clinical Pharmacogenomics of Antidepressant Response

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital
Mackay Memorial Hospital
National Science Council, Taiwan
Song-De, Taipei City Hospital, Taiwan
Taipei City Hospital
Taipei Medical University WanFang Hospital
Treatments:
Antidepressive Agents
Citalopram
Paroxetine